Literature DB >> 23505573

Hepatic encephalopathy associated with cancer or anticancer therapy.

Kaspar J Willson1, Louise M Nott, Vy T Broadbridge, Timothy Price.   

Abstract

Hepatic encephalopathy is an uncommon cause of neurologic deterioration associated with hyperammonemia, which results from hepatic dysfunction or altered ammonia metabolism. Often overlooked, hyperammonemia may occur via any of several pathophysiological processes, and in the setting of malignancy, it is a potentially reversible cause of confusion and coma. Hepatic dysfunction as a result of malignant infiltration, chemotherapeutic toxicities, targeted anticancer therapies, reactivation hepatitis, portosystemic shunting, and transarterial chemoembolization (TACE) is discussed, and an approach to etiological diagnosis and management is outlined.

Entities:  

Year:  2013        PMID: 23505573      PMCID: PMC3597933     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN: 1934-7820


  82 in total

Review 1.  Idiopathic hyperammonemia (IHA) after dose-dense induction chemotherapy for acute myeloid leukemia: Case report and review of the literature.

Authors:  Klaus H Metzeler; Stefan Boeck; Birgit Christ; Andreas Hausmann; Hans-Joachim Stemmler; Klaus G Parhofer; Helmut Ostermann; Wolfgang Hiddemann; Jan Braess
Journal:  Leuk Res       Date:  2009-02-23       Impact factor: 3.156

2.  Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Salvatore Guastafierro; Gilda Tonziello; Antonello Sica; Valentina Iodice; Caterina Sagnelli; Maria Giovanna Ferrara; Evangelista Sagnelli
Journal:  Dig Liver Dis       Date:  2011-08-31       Impact factor: 4.088

3.  Hepatic coma secondary to metastatic liver disease.

Authors:  P Eras; P Sherlock
Journal:  Ann Intern Med       Date:  1971-04       Impact factor: 25.391

4.  Redevelopment of hepatitis B surface antigen after renal transplantation.

Authors:  P Marcellin; E Giostra; M Martinot-Peignoux; M A Loriot; M L Jaegle; P Wolf; C Degott; F Degos; J P Benhamou
Journal:  Gastroenterology       Date:  1991-05       Impact factor: 22.682

5.  Etiology, management, and outcome of the Budd-Chiari syndrome.

Authors:  Sarwa Darwish Murad; Aurelie Plessier; Manuel Hernandez-Guerra; Federica Fabris; Chundamannil E Eapen; Matthias J Bahr; Jonel Trebicka; Isabelle Morard; Luc Lasser; Joerg Heller; Antoine Hadengue; Philippe Langlet; Helena Miranda; Massimo Primignani; Elwyn Elias; Frank W Leebeek; Frits R Rosendaal; Juan-Carlos Garcia-Pagan; Dominique C Valla; Harry L A Janssen
Journal:  Ann Intern Med       Date:  2009-08-04       Impact factor: 25.391

Review 6.  Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy.

Authors:  Louise Nott; Timothy J Price; Ken Pittman; Kevin Patterson; Janice Fletcher
Journal:  Leuk Lymphoma       Date:  2007-09

7.  Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

Authors:  A S Lok; R H Liang; E K Chiu; K L Wong; T K Chan; D Todd
Journal:  Gastroenterology       Date:  1991-01       Impact factor: 22.682

8.  Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.

Authors:  Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

9.  American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.

Authors:  Andrew S Artz; Mark R Somerfield; Jordan J Feld; Andrew F Giusti; Barnett S Kramer; Anita L Sabichi; Robin T Zon; Sandra L Wong
Journal:  J Clin Oncol       Date:  2010-06-01       Impact factor: 44.544

10.  Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy.

Authors:  W Yeo; B Zee; S Zhong; P K S Chan; W-L Wong; W M Ho; K C Lam; P J Johnson
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

View more
  9 in total

1.  Chemotherapy in a Breast Cancer Patient Heterozygous Carrier of Ornithine Transcarbamylase Deficiency.

Authors:  Magda Palka-Kotlowska; Luis Cabezón-Gutiérrez; Sara Custodio-Cabello; PIlar Quijada-Fraile; Silvia Chumillas-Calzada
Journal:  Cureus       Date:  2020-05-26

Review 2.  Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.

Authors:  Xi-Feng Jin; Matilde P Spampatti; Christine Spitzweg; Christoph J Auernhammer
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

3.  Insights into accelerated liposomal release of topotecan in plasma monitored by a non-invasive fluorescence spectroscopic method.

Authors:  Kyle D Fugit; Amar Jyoti; Meenakshi Upreti; Bradley D Anderson
Journal:  J Control Release       Date:  2014-10-25       Impact factor: 9.776

4.  Prognostic factors of unresectable hepatocellular carcinoma treated with yttrium-90 radioembolization: results from a large cohort over 13 years at a single center.

Authors:  Rucha M Shah; Sarah Sheikh; Jimmy Shah; Elaina Vivian; Alejandro Mejia; Islam Shahin; Parvez S Mantry
Journal:  J Gastrointest Oncol       Date:  2021-08

5.  Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment.

Authors:  Karlijn Verkerk; Hans-Martin Otten; Alwin D R Huitema
Journal:  Cancer Chemother Pharmacol       Date:  2022-09-20       Impact factor: 3.288

Review 6.  Clinical and biochemical footprints of inherited metabolic diseases. VIII. Neoplasias.

Authors:  Teodoro Jerves; Nenad Blau; Carlos R Ferreira
Journal:  Mol Genet Metab       Date:  2022-03-28       Impact factor: 4.204

7.  Hyperammonemic encephalopathy in an adenocarcinoma patient managed with carglumic acid.

Authors:  J Lazier; S M Lupichuk; I Sosova; A A Khan
Journal:  Curr Oncol       Date:  2014-10       Impact factor: 3.677

8.  Unexpected side effect in mCRC: A care-compliant case report of regorafenib-induced hyperammonemic encephalopathy.

Authors:  Michela Quirino; Sabrina Rossi; Giovanni Schinzari; Michele Basso; Antonia Strippoli; Alessandra Cassano; Carlo Barone
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

9.  A 5-Fluorouracil-Induced Hyperammonemic Encephalopathy Challenged with Capecitabine.

Authors:  Michael Chahin; Nithya Krishnan; Hardik Chhatrala; Marwan Shaikh
Journal:  Case Rep Oncol Med       Date:  2020-01-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.